Gastro Medical News about Inflammatory Bowel Diseases

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The impact of biologics on health-related quality of life in patients with inflammatory bowel disease
Clinical and Experimental Gastroenterology, 09/28/09

Vogelaar L et al. – The biologics infliximab, adalimumab, certolizumab, and natalizumab demonstrated significant improvement of HRQoL of IBD patients compared with placebo. However, the authors found differences in improvement of HRQoL between the different biologics.

<< Previous
Diagnostic findings of ultrasound-guided fine-needle aspiration...

Next >>
Application of endoscopic hemoclips for nonvariceal bleeding in...